PDCD1 and non-small cell lung carcinoma: In recent years, immunotherapy based on monoclonal antibodies targeting immune checkpoint programmed cell death-1 (PD-1) and programmed cell death-1 ligand (PD-L1) has achieved remarkable clinical success and shown unprecedented durable responses for NSCLC patients without an actionable driver mutation (5–8).